[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636718":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":52,"collaborators":32,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":32,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":32,"enrollmentInfo":65,"targetDuration":32,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":32,"overallStatus":76,"whyStopped":32,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Colchicine group","EXPERIMENTAL","Patients are randomized within 3 days after successful isolated CABG, and on the day of randomization, eligible patients receive guideline-directed standard secondary prevention therapy plus colchicine (0.5 mg qd) starting as soon as possible (within 24 hours) and continuing for 24 months.",[13],"Drug: Colchicine Pill",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Patients are randomized within 3 days after successful isolated CABG, and on the day of randomization, eligible patients receive guideline-directed standard secondary prevention therapy plus matching placebo (1 tablet qd) starting as soon as possible (within 24 hours) and continuing for 24 months.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Colchicine Pill","Colchicine 0.5 mg once daily will be given on the basis of guideline-recommended standard secondary prevention therapy after CABG for 24 months.",[9],[27],"Colchicine 0.5 MG",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Placebo one tablet once daily will be given on the basis of guideline-recommended standard secondary prevention therapy after CABG for 24 months.",[15],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Xiaoli Liu, PhD, MD","CONTACT","8613581633895","liuxiaoli@ccmu.edu.cn",[40],{"facility":5,"status":32,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":32},"Beijing","Beijing Municipality","100029","China","CN",{"type":47,"coordinates":48},"Point",[49,50],116.39723,39.9075,{"lat":50,"lon":49},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Liu Xiaoli","Professor","100636718","low-dose-colchicine-for-cabg-graft-failure-prevention-100636718",false,"NCT07569328","Low-dose Colchicine for CABG Graft Failure Prevention","Low-dose Colchicine for CABG Graft Failure Prevention: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Be male or female, aged 18 years or older;\n2. Within 3 days after successful isolated coronary artery bypass grafting (CABG);\n3. Sign informed consent;\n\nExclusion Criteria:\n\n1. Severe valvular heart disease requiring concomitant or staged valvular surgery;\n2. History of non-skin cancer in the past 3 years;\n3. Inflammatory bowel disease or chronic diarrhea;\n4. Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);\n5. Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities (Hemoglobin \\\u003C100g\u002FL or hematocrit \\\u003C 30% or \\> 52% or white blood cell count \\\u003C 3×109\u002FL or platelet count \\\u003C 100×109\u002FL);\n6. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² (based on the CKDEPI formula);\n7. Serum alanine aminotransferase and\u002For aspartate aminotransferase levels greater than 2 times the upper limit of the normal range, accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders (INR\\>1.5) (except for elevated glutamic oxalacetic transaminase associated with myocardial infarction);\n8. Decline in cognitive function due to inability to perform basic activities of daily living independently;\n9. Drug or alcohol abuse;\n10. Other immunosuppressive therapies already in existence or planned;\n11. Other causes require long-term colchicine treatment;\n12. History of clear or suspected colchicine allergy;\n13. Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.","ALL","18 Years",{"count":66,"type":67},622,"ESTIMATED","INTERVENTIONAL",[70],"NA","This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.",[73,74,75],"CAD - Coronary Artery Disease","CABG","Colchicine","NOT_YET_RECRUITING","2026-04-29",{"date":79,"type":80},"2026-05-06","ACTUAL",{"date":82,"type":67},"2026-09-01",{"date":84,"type":67},"2029-09-01",{"name":5,"class":6},1]